Table 3.

Schedule of participants visits for data collection and monitoring, years 1-5.

Test	Year 1			Year 2				Year 3				Year 4				Year 5
	Qa2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3		Q4
Stanford 25 comprehensive clinical assessment				X				X				X				X
Spirometry (FVCb, FEVc, FEV1d, FEV1/ FVC, FEFe 25-75, MEFf), bronchodilation test using salbutamol				X				X				X				X
CATg				X				X				X				X
6MWTg				X				X				X				X
Short form-12 Quality of Life questionnaire				X				X				X				X
ECGg				X				X				X				X
Body mass index				X				X				X				X
Smoking status, exposures				X				X				X				X
Laboratory testing for blood cholesterol level, CBCj (25 parameters); HDLk, LDLl, triglycerides, C-reactive protein, fibrinogen, glucose, glycosylated hemoglobin				X				X				X				X
Biomarker testing for sRAGEm, ICAM1n, and CCL20o				X				X				X				X
Lung computer tomography				X				X				X				X
Continuous health status monitoring, including home visits, phone, email, telemedicine, and COPDp Center visits as necessary	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X	X
Monitoring COPD exacerbations based on use of inhaled steroids, antibiotics, inhaled bronchodilators, steroids, health care visits (office visits, emergency department, or hospital)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X	X
Monitoring adverse events and serious adverse events using SymptoMaster self-assessment that triggers notification	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X

^aQ: quarter.

^bFVC: forced vital capacity.

^cFEV: forced expiratory volume.

^dFEV1: forced expiratory volume in 1 second.

^eFEF: forced expiratory flow.

^fMEF: maximum expiratory flow.

^gCAT: COPD Assessment Test.

^h6MWT: 6-Minute Walk Test.

ⁱECG: electrocardiogram.

^jCBC: complete blood count.

^kHDL: high-density lipoproteins.

^lLDL: low-density lipoproteins.

^msRAGE: advanced glycosylation end-product receptor.

ⁿICAM1: intercellular adhesion molecule 1.

^oCCL20: macrophage inhibitory protein 3a.

^pCOPD: chronic obstructive pulmonary disease.